bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
Authors: Wu Jenny , Clingen Peter H. , Spanswick Victoria J. , Mellinas-Gomez Maria , Meyer Tim , Puzanov Igor , Jodrell Duncan , Hochhauser Daniel , Hartley John A.
Published: April 2023

PDF file - 56K, Mean foci per cell versus dose of SJG-136 administered for the CRUK (upper) and NCI (middle) clinical trials, and mean foci per cell versus cross-linking (% decrease in tail moment) for the NCI trial (bottom).
Supplementary Figure 2 from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
Authors: Wu Jenny , Clingen Peter H. , Spanswick Victoria J. , Mellinas-Gomez Maria , Meyer Tim , Puzanov Igor , Jodrell Duncan , Hochhauser Daniel , Hartley John A.
Published: April 2023

PDF file - 59K, Validation experiments in human lymphocytes treated ex vivo with SJG-136. A. Inter-assay variation - mean � s.e. data from three independent experiments. B. Intra-assay variation - mean � s.e. data from the same samples assayed on three independent occasions. C. Aliquots of the same internal standard samples stored at -80oC were assayed with each set of clinical samples. Data are the mean � s.e. from 10 internal standard runs over a period of several months.
Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
Authors: Noonan Anne M. , Eisch Robin A. , Liewehr David J. , Sissung Tristan M. , Venzon David J. , Flagg Thomas P. , Haigney Mark C. , Steinberg Seth M. , Figg William D. , Piekarz Richard L. , Bates Susan E.
Published: April 2023

Supplementary Figure 6 - PDF file 60K, Changes in heart rate observed for each patient in the NIH cohort during cycle 2 days 1, 8 and 15, excluding the patients taking beta-blockers
Supplementary Figure 2 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Authors: Karbach Julia , Neumann Antje , Brand Kathrin , Wahle Claudia , Siegel Ekkehard , Maeurer Markus , Ritter Erika , Tsuji Takamasa , Gnjatic Sacha , Old Lloyd J. , Ritter Gerd , Jäger Elke
Published: April 2023

PDF file, 64K, In-vitro immunostimulatory activity of MBV on PBMC.
Supplementary Figure 1 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Authors: Karbach Julia , Neumann Antje , Brand Kathrin , Wahle Claudia , Siegel Ekkehard , Maeurer Markus , Ritter Erika , Tsuji Takamasa , Gnjatic Sacha , Old Lloyd J. , Ritter Gerd , Jäger Elke
Published: April 2023

PDF file, 82K, Trial design schema.
Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
Authors: Noonan Anne M. , Eisch Robin A. , Liewehr David J. , Sissung Tristan M. , Venzon David J. , Flagg Thomas P. , Haigney Mark C. , Steinberg Seth M. , Figg William D. , Piekarz Richard L. , Bates Susan E.
Published: April 2023

Supplemental Tables - PDF file 76K, Table S1. Diplotype arrangements of the ABCB1 SNPs calculated using Haploview. (Reproduced with authors' permission, Sissung et al, 2011(13); Table S2. Analysis of reported cardiovascular events for all 131 patients in NCI 1312; Table S3. Statistical Analyzes of Albumin, Potassium & Magnesium Data; Table S4. Analysis of variance to examine the relationship between albumin, potassium and magnesium levels in patients treated on NCI 1312; table legends
Supplementary Figure 3 from Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma
Authors: Ni Dong , Ma Xin , Li Hong-Zhao , Gao Yu , Li Xin-Tao , Zhang Yu , Ai Qing , Zhang Peng , Song Er-Lin , Huang Qing-Bo , Fan Yang , Zhang Xu
Published: April 2023

PDF file - 2206KB, Scratch wound migration assays in the 786-O and SN12-PM6 cells.
Supplementary Figure 2 from Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma
Authors: Ni Dong , Ma Xin , Li Hong-Zhao , Gao Yu , Li Xin-Tao , Zhang Yu , Ai Qing , Zhang Peng , Song Er-Lin , Huang Qing-Bo , Fan Yang , Zhang Xu
Published: April 2023

PDF file - 136KB, Analysis of expression profiling data for filtering central genes.
Supplementary Figure 5 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Authors: Murphy Katherine A. , Lechner Melissa G. , Popescu Flavia E. , Bedi Jessica , Decker Stacy A. , Hu Peisheng , Erickson Jami R. , O'Sullivan M. Gerard , Swier Lauryn , Salazar Andres M. , Olin Michael R. , Epstein Alan L. , Ohlfest John R.
Published: April 2023

PDF file, 380K, Histological Analysis of secondary malignancies.
Supplementary Figure 4 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Authors: Murphy Katherine A. , Lechner Melissa G. , Popescu Flavia E. , Bedi Jessica , Decker Stacy A. , Hu Peisheng , Erickson Jami R. , O'Sullivan M. Gerard , Swier Lauryn , Salazar Andres M. , Olin Michael R. , Epstein Alan L. , Ohlfest John R.
Published: April 2023

PDF file, 150K, Efficacy of vaccine/Fc-OX40L treatment in an orthotopic breast carcinoma.
Supplementary Figure Legends, Tables 1 - 2 from A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Authors: Rodon Jordi , Tawbi Hussein A. , Thomas Anne L. , Stoller Ronald G. , Turtschi Christian P. , Baselga Jose , Sarantopoulos John , Mahalingam Devalingam , Shou Yaping , Moles Melissa A. , Yang Lin , Granvil Camille , Hurh Eunju , Rose Kristine L. , Amakye Dereck D. , Dummer Reinhard , Mita Alain C.
Published: April 2023

PDF file - 71K, Supplementary data includes a table summarizing cohort enrollment and dose-limiting toxicities (Table S1) and a table showing the association between tumor response and Hh pathway activity in medulloblastoma and basal cell carcinoma (Table S2).
Supplementary Figure 3 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Authors: Murphy Katherine A. , Lechner Melissa G. , Popescu Flavia E. , Bedi Jessica , Decker Stacy A. , Hu Peisheng , Erickson Jami R. , O'Sullivan M. Gerard , Swier Lauryn , Salazar Andres M. , Olin Michael R. , Epstein Alan L. , Ohlfest John R.
Published: April 2023

PDF file, 239K, The components of the vaccine/Fc-OX40L treatment were broken down to determine which components were necessary for maximal effect.
Supplementary Figure 3 from A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Authors: Rodon Jordi , Tawbi Hussein A. , Thomas Anne L. , Stoller Ronald G. , Turtschi Christian P. , Baselga Jose , Sarantopoulos John , Mahalingam Devalingam , Shou Yaping , Moles Melissa A. , Yang Lin , Granvil Camille , Hurh Eunju , Rose Kristine L. , Amakye Dereck D. , Dummer Reinhard , Mita Alain C.
Published: April 2023

PDF file - 624K, Relationship between sonidegib area under the plasma concentration-time curve on day 15 and the incidence of grade 3/4 creatine kinase elevation.
Supplementary Figure 1 from A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Authors: Rodon Jordi , Tawbi Hussein A. , Thomas Anne L. , Stoller Ronald G. , Turtschi Christian P. , Baselga Jose , Sarantopoulos John , Mahalingam Devalingam , Shou Yaping , Moles Melissa A. , Yang Lin , Granvil Camille , Hurh Eunju , Rose Kristine L. , Amakye Dereck D. , Dummer Reinhard , Mita Alain C.
Published: April 2023

PDF file - 29K, Chemical structures of sonidegib and cyclopamine.
Supplementary Figure Legend from Nupr1-Aurora Kinase A Pathway Provides Protection against Metabolic Stress-Mediated Autophagic-Associated Cell Death
Authors: Hamidi Tewfik , Cano Carla E. , Grasso Daniel , Garcia Maria Noé , Sandi Maria José , Calvo Ezequiel L. , Dagorn Jean-Charles , Lomberk Gwen , Urrutia Raul , Goruppi Sandro , Carracedo Arkaitz , Velasco Guillermo , Iovanna Juan L.
Published: April 2023

PDF file, 61K.
Supplementary Table 2 from Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation
Authors: Duan Zhenfeng , Zhang Jianming , Choy Edwin , Harmon David , Liu Xianzhe , Nielsen Petur , Mankin Henry , Gray Nathanael S. , Hornicek Francis J.
Published: April 2023

PDF file, 99K, Comparison of the clinical characteristics of 58 patients with CDK11 low-staining (<=3)and high-staining (>=4) of osteosarcoma.
Supplementary Figure 5 from Nupr1-Aurora Kinase A Pathway Provides Protection against Metabolic Stress-Mediated Autophagic-Associated Cell Death
Authors: Hamidi Tewfik , Cano Carla E. , Grasso Daniel , Garcia Maria Noé , Sandi Maria José , Calvo Ezequiel L. , Dagorn Jean-Charles , Lomberk Gwen , Urrutia Raul , Goruppi Sandro , Carracedo Arkaitz , Velasco Guillermo , Iovanna Juan L.
Published: April 2023

PDF file, 137K, Protective role of Nupr1 and AURKA in BxPC-3 cells.
Supplementary Figure 2C-F from Stromal Responses among Common Carcinomas Correlated with Clinicopathologic Features
Authors: Chen Julia L-Y. , Espinosa Iñigo , Lin Albert Y. , Liao Olivia Y-W. , van de Rijn Matt , West Robert B.
Published: April 2023

PDF file, 249K, The expression profiles of DTF fibroblast core gene signature in two colon cancer datasets, including GSE 14333 (Supp Fig2A) and GSE17538 (Supp Fig2B). The results of the survival analysis of GSE14333 and GSE17538 were separately shown in Supp Fig2C and Supp Fig2D, Supp Fig2E and Supp Fig2F.
Supplementary Figure 2A-B from Stromal Responses among Common Carcinomas Correlated with Clinicopathologic Features
Authors: Chen Julia L-Y. , Espinosa Iñigo , Lin Albert Y. , Liao Olivia Y-W. , van de Rijn Matt , West Robert B.
Published: April 2023

PDF file, 829K, The expression profiles of DTF fibroblast core gene signature in two colon cancer datasets, including GSE 14333 (Supp Fig2A) and GSE17538 (Supp Fig2B). The results of the survival analysis of GSE14333 and GSE17538 were separately shown in Supp Fig2C and Supp Fig2D, Supp Fig2E and Supp Fig2F.
Supplementary Figure Legends from TGF-β–Induced Upregulation of malat1 Promotes Bladder Cancer Metastasis by Associating with suz12
Authors: Fan Yu , Shen Bing , Tan Mingyue , Mu Xinyu , Qin Yan , Zhang Fang , Liu Yong
Published: April 2023

PDF file - 89K
Supplementary Figure 6 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Authors: Brauer Matthew J. , Zhuang Guanglei , Schmidt Maike , Yao Jenny , Wu Xiumin , Kaminker Joshua S. , Jurinka Stefanie S. , Kolumam Ganesh , Chung Alicia S. , Jubb Adrian , Modrusan Zora , Ozawa Tomoko , James C. David , Phillips Heidi , Haley Benjamin , Tam Rachel N.W. , Clermont Anne C. , Cheng Jason H. , Yang Sherry X. , Swain Sandra M. , Chen Daniel , Scherer Stefan J. , Koeppen Hartmut , Yeh Ru-Fang , Yue Peng , Stephan Jean-Philippe , Hegde Priti , Ferrara Napoleone , Singh Mallika , Bais Carlos
Published: April 2023

PDF file - 83K, Fig S6. Effect of VDV gene expression and bevacizumab treatment in OS.
Supplementary Figure 5 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Authors: Brauer Matthew J. , Zhuang Guanglei , Schmidt Maike , Yao Jenny , Wu Xiumin , Kaminker Joshua S. , Jurinka Stefanie S. , Kolumam Ganesh , Chung Alicia S. , Jubb Adrian , Modrusan Zora , Ozawa Tomoko , James C. David , Phillips Heidi , Haley Benjamin , Tam Rachel N.W. , Clermont Anne C. , Cheng Jason H. , Yang Sherry X. , Swain Sandra M. , Chen Daniel , Scherer Stefan J. , Koeppen Hartmut , Yeh Ru-Fang , Yue Peng , Stephan Jean-Philippe , Hegde Priti , Ferrara Napoleone , Singh Mallika , Bais Carlos
Published: April 2023

PDF file - 154K, Fig S5. Most proxVDV genes are not obviously up-regulated by rVEGF in vitro.
Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Authors: Manceau Gilles , Imbeaud Sandrine , Thiébaut Raphaële , Liébaert François , Fontaine Karine , Rousseau Francis , Génin Bérengère , Corre Delphine Le , Didelot Audrey , Vincent Marc , Bachet Jean-Baptiste , Chibaudel Benoist , Bouché Olivier , Landi Bruno , Bibeau Frédéric , Leroy Karen , Penault-Llorca Frédérique , Van Laethem Jean-Luc , Demetter Pieter , Tejpar Sabine , Rossi Simona , Mosakhani Neda , Österlund Pia , Ristamäki Raija , Sarhadi Virinder , Knuutila Sakari , Boige Valérie , André Thierry , Laurent-Puig Pierre
Published: April 2023

PDF file - 64KB, Regression analysis of the log transformed hsa-miR-31-3p and gene expression levels plotted on x-axis and y-axis, respectively. The name of the gene and correlation p-values between expression values are indicated in the main title. Intervals specify computation of confidence (in red) or prediction (tolerance, in blue) intervals at 0.95 levels.
Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Authors: Manceau Gilles , Imbeaud Sandrine , Thiébaut Raphaële , Liébaert François , Fontaine Karine , Rousseau Francis , Génin Bérengère , Corre Delphine Le , Didelot Audrey , Vincent Marc , Bachet Jean-Baptiste , Chibaudel Benoist , Bouché Olivier , Landi Bruno , Bibeau Frédéric , Leroy Karen , Penault-Llorca Frédérique , Van Laethem Jean-Luc , Demetter Pieter , Tejpar Sabine , Rossi Simona , Mosakhani Neda , Österlund Pia , Ristamäki Raija , Sarhadi Virinder , Knuutila Sakari , Boige Valérie , André Thierry , Laurent-Puig Pierre
Published: April 2023

PDF file - 60KB, The red spot indicates the area under the curve superior to 0.7 for predicting the PFS at different endpoints, blue spot indicates the area under the curve superior to 0.64 which corresponds to the mean of the area under the curve for predicting the PFS at different endpoints.
Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Authors: Manceau Gilles , Imbeaud Sandrine , Thiébaut Raphaële , Liébaert François , Fontaine Karine , Rousseau Francis , Génin Bérengère , Corre Delphine Le , Didelot Audrey , Vincent Marc , Bachet Jean-Baptiste , Chibaudel Benoist , Bouché Olivier , Landi Bruno , Bibeau Frédéric , Leroy Karen , Penault-Llorca Frédérique , Van Laethem Jean-Luc , Demetter Pieter , Tejpar Sabine , Rossi Simona , Mosakhani Neda , Österlund Pia , Ristamäki Raija , Sarhadi Virinder , Knuutila Sakari , Boige Valérie , André Thierry , Laurent-Puig Pierre
Published: April 2023

PDF file - 62KB, Kaplan-Meier curve for PFS according to the classification in high risk and low risk patients by the level of expression of 11 microRNAs.
Supplementary Figure Legends from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
Authors: Candolfi Marianela , Yagiz Kader , Wibowo Mia , Ahlzadeh Gabrielle E. , Puntel Mariana , Ghiasi Homayon , Kamran Neha , Paran Christopher , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

PDF file - 92K
Supplementary Table 4 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Authors: Davies Kurtis D. , Le Anh T. , Theodoro Mariana F. , Skokan Margaret C. , Aisner Dara L. , Berge Eamon M. , Terracciano Luigi M. , Cappuzzo Federico , Incarbone Matteo , Roncalli Massimo , Alloisio Marco , Santoro Armando , Camidge D. Ross , Varella-Garcia Marileila , Doebele Robert C.
Published: April 2023

PDF file - 37K, Clinical and histopathologic features of patients screened for ROS1 at the University of Colorado
Supplementary Figure 3 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
Authors: Candolfi Marianela , Yagiz Kader , Wibowo Mia , Ahlzadeh Gabrielle E. , Puntel Mariana , Ghiasi Homayon , Kamran Neha , Paran Christopher , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

PDF file - 884K, Efficacy of TMZ in combination with Ad-TK and Ad-Flt3L in intracranial astrocytoma and melanoma models.
Supplementary Figure Legends 1-3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Authors: Davies Kurtis D. , Le Anh T. , Theodoro Mariana F. , Skokan Margaret C. , Aisner Dara L. , Berge Eamon M. , Terracciano Luigi M. , Cappuzzo Federico , Incarbone Matteo , Roncalli Massimo , Alloisio Marco , Santoro Armando , Camidge D. Ross , Varella-Garcia Marileila , Doebele Robert C.
Published: April 2023

PDF file - 42K
Supplementary Figure 3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Authors: Davies Kurtis D. , Le Anh T. , Theodoro Mariana F. , Skokan Margaret C. , Aisner Dara L. , Berge Eamon M. , Terracciano Luigi M. , Cappuzzo Federico , Incarbone Matteo , Roncalli Massimo , Alloisio Marco , Santoro Armando , Camidge D. Ross , Varella-Garcia Marileila , Doebele Robert C.
Published: April 2023

PDF file - 397K, Western blot analysis of signaling pathways in Ba/F3 cells expressing ROS1 gene fusion
Supplementary Figure 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Authors: Davies Kurtis D. , Le Anh T. , Theodoro Mariana F. , Skokan Margaret C. , Aisner Dara L. , Berge Eamon M. , Terracciano Luigi M. , Cappuzzo Federico , Incarbone Matteo , Roncalli Massimo , Alloisio Marco , Santoro Armando , Camidge D. Ross , Varella-Garcia Marileila , Doebele Robert C.
Published: April 2023

PDF file - 322K, Micrographs of H&E and IHC of two squamous cell ROS1 positive cases
Supplementary Tables 1 - 8 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Authors: Collinson Fiona , Hutchinson Michelle , Craven Rachel A. , Cairns David A. , Zougman Alexandre , Wind Tobias C. , Gahir Narinder , Messenger Michael P. , Jackson Sharon , Thompson Douglas , Adusei Cybil , Ledermann Jonathan A. , Hall Geoffrey , Jayson Gordon C. , Selby Peter J. , Banks Rosamonde E.
Published: April 2023

PDF file - 129K, Supplementary Table 1. Clinical characteristics of discovery cohort. Characteristics of 10 patients from experimental arm of ICON7 trial used in MS discovery experiment; Supplementary Table 2. Number of samples in each treatment arm at each time-point; Supplementary Table 3 Associations between the baseline concentrations (time-point 1) of the serum biomarkers under investigation and the clinical characteristics in the validation study in validation cohort II; Supplementary Table 4 Associations between the baseline concentrations (time-point 1) of the serum biomarkers under investigation and the clinical characteristics in the validation study in both validation cohorts (validation cohort I and validation cohort II); Supplementary Table 5. Estimates from Cox proportional hazards regression for biomarker index (signature negative index < 3 and positive index ≥3), trial arm (standard or experimental) and signature/trial arm interaction in each validation cohort; Supplementary Table 6. Estimates from Cox proportional hazards regression for individual elements of biomarker index (score=1 if marker concentration is on the side of the cut-point favouring bevacizumab in terms of PFS in the optimal model for that marker, or a score=0 otherwise), trial arm (standard or experimental) and index element/trial arm interaction; Supplementary Table 7. Estimates from Cox proportional hazards regression for all possible combinations of the elements of the biomarker index (score=1 if the sum of the combination of elements ≥optimal split, or a score=0 otherwise, where the optimal split is recalculated for each model combination), trial arm (standard or experimental) and model combination score/trial arm interaction; Supplementary Table 8. Estimates from Cox proportional hazards regression for individual elements of biomarker index treated as continuous, trial arm (standard or experimental) and index element/trial arm interaction
Supplementary Figure Legend from Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
Authors: Guichelaar Teun , Emmelot Maarten E. , Rozemuller Henk , Martini Bianka , Groen Richard W.J. , Storm Gert , Lokhorst Henk M. , Martens Anton C. , Mutis Tuna
Published: April 2023

PDF file - 53K
Supplementary Figure 2 from Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1
Authors: Wang Rui , Liu Changda , Xia Lijuan , Zhao Guisen , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

PDF file - 163K, Silencing of XIAP, survivin, or Bcl-xL in K562 cells
Supplementary Figure 1 from Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1
Authors: Wang Rui , Liu Changda , Xia Lijuan , Zhao Guisen , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

PDF file - 88K, Apoptosis detection by FACS in HL-60 and K562
Supplementary Tables 7 - 8 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer
Authors: Patani Neill , Dunbier Anita K. , Anderson Helen , Ghazoui Zara , Ribas Ricardo , Anderson Elizabeth , Gao Qiong , A'hern Roger , Mackay Alan , Lindemann Justin , Wellings Robert , Walker Jill , Kuter Irene , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

PDF file - 147KB, S7: Ingenuity based analysis of genes affected by E-deprivation: (a) In vitro and (b) FAIMoS (two weeks) detailing (i) canonical pathways (p<0.01) and (ii) top ten networks and functions; S8: Ingenuity based analysis of genes affected by fulvestrant: (a) In vitro and (b) NEWEST (high-dose), detailing (i) canonical pathways (p<0.01) and (ii) top ten networks and functions.
Supplementary Figure Legend from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Authors: Miao Yu Rebecca , Eckhardt Bedrich L. , Cao Yuan , Pasqualini Renata , Argani Pedram , Arap Wadih , Ramsay Robert G. , Anderson Robin L.
Published: April 2023

PDF file - 69K
Supplementary Figure 5 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Authors: Miao Yu Rebecca , Eckhardt Bedrich L. , Cao Yuan , Pasqualini Renata , Argani Pedram , Arap Wadih , Ramsay Robert G. , Anderson Robin L.
Published: April 2023

PDF file - 425K, Supplementary Figure 5. Body weights of mice bearing 4T1.2 mammary tumors during treatment with BMTP78 or control peptide or saline.
Supplementary Figure 4 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Authors: Miao Yu Rebecca , Eckhardt Bedrich L. , Cao Yuan , Pasqualini Renata , Argani Pedram , Arap Wadih , Ramsay Robert G. , Anderson Robin L.
Published: April 2023

PDF file - 151K, Supplementary Figure 4. Effect of cell growth in different concentrations of oxygen on the extent of surface GRP78 in normal and transformed human and mouse cells.
Supplementary Figure 1 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Authors: Miao Yu Rebecca , Eckhardt Bedrich L. , Cao Yuan , Pasqualini Renata , Argani Pedram , Arap Wadih , Ramsay Robert G. , Anderson Robin L.
Published: April 2023

PDF file - 735K, Supplementary Figure 1. Details of the analysis of cell surface GRP78 levels using flow cytometry.
Supplementary Table 3 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

XLSX file - 63K, Microarray Notch pathway components gene expression data on 443 human lung adenocarcinomas.
Supplementary Figure S2 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer
Authors: Zhang Geng , He Peijun , Tan Hanson , Budhu Anuradha , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Maitra Anirban , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Supplementary Figure S2 - PDF file 119K, Palmitate and Stearate inhibits cell growth of pancreatic cancer cell lines
Supplementary Figure Legends from Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Authors: Bäumer Sebastian , Bäumer Nicole , Appel Neele , Terheyden Lisa , Fremerey Julia , Schelhaas Sonja , Wardelmann Eva , Buchholz Frank , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Legends for supplementary figures.
Supplementary Table S4 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Association between the score from the three-marker signature and the recurrent bladder tumor pathological characteristics of 34 recurrence patients.
Supplementary Table S3 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Association between the score from the three-marker signature and the primary bladder tumor pathological characteristics of 90 TURBT patients.
Supplementary Table S1 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

DNA methylation status in urine sediment samples of TURBT patients at the time of first recurrence and the last follow-up visit of no recurrence patients.
Supplementary Figure 2 from Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Authors: Bäumer Sebastian , Bäumer Nicole , Appel Neele , Terheyden Lisa , Fremerey Julia , Schelhaas Sonja , Wardelmann Eva , Buchholz Frank , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Supplementary Figure 2. Anti-EGFR antibody-directed EZH2-RNAi reduces EZH2 expression in EGFR-expressing carcinoma cell lines/overview of cell lines used in this study.
Supplementary Materials from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

PDF file - 68KB
Supplementary Figure S4 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Three DNA methylation markers help predict the risk of recurrence of bladder tumors in urine sediments.
Supplementary Figure S2 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Spearman correlation of DNA methylation levels of each marker in urine sediment samples of TURBT patients.
Supplementary Table 1 from Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
Authors: Brauer Heather Ann , Makowski Liza , Hoadley Katherine A. , Casbas-Hernandez Patricia , Lang Lindsay J. , Romàn-Pèrez Erick , D'Arcy Monica , Freemerman Alex J. , Perou Charles M. , Troester Melissa A.
Published: April 2023

PDF file - 625K, Raw metabolomics data for all samples.
Supplementary Figure Legends from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Supplementary Figure Legends
Supplementary Tables 1 - 2 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 67KB, Supplementary Table S1: Quantitation of pY changes in between PC9 and PC9GR cell lines with and without erlotinib treatment. The cutoff was set as P value<0.05, fold change >1.5; Supplementary Table S2: Cell viability IC50 in PC9GR cells and H1975 cells.
S1: supplementary table from Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy
Authors: Weber Gerrit , Caruana Ignazio , Rouce Rayne H. , Barrett A. John , Gerdemann Ulrike , Leen Ann M. , Rabin Karen R. , Bollard Catherine M.
Published: April 2023

S1: supplementary table - PDF file 61K, S1: supp. table
Supplementary Table 3A - B from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 95KB, Supplementary Table S3-A. Human tumor pY proteome. S3-B. Comparison analysis of unique pTyr sites iden_fy from di_erent samples.
Supplementary Figure 5 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 91KB, A: Effects of dasatinib combined with afatinib on apoptosis in HCC4006-T790M and HCC827-T790M cells. Apoptosis assay was carried out using PE-conjugated caspase-3 antibody, following incubation of HCC4006-T790M or HCC827-T790M cells for 72 hours with DMSO, erlotinib (E), dasatinib (D), afatinib (A), and afatinib + dasatinib. Values are expressed as a percentage of caspase-3-positive cells. Determinations were done in triplicate. Bars, SD. *P < 0.001 versus DMSO or each single agent (Student's t-test). B: Validation of active pTyr sites from PC9 cell lines on lung cancer patient. Venn diagram was used to compare the pTyr sites identified from PC9 and human lung tumor tissue with positive EGFR mutation. Total 83 overlap active pTyr sites were obtained.
Supplementary Figure 4 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 139KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplementary Table 1 from Discovery and Prevalidation of Salivary Extracellular microRNA Biomarkers Panel for the Noninvasive Detection of Benign and Malignant Parotid Gland Tumors
Authors: Matse Johannes H. , Yoshizawa Janice , Wang Xiaoyan , Elashoff David , Bolscher Jan G.M. , Veerman Enno C.I. , Bloemena Elisabeth , Wong David T.W.
Published: April 2023

XLSX file - 240K, Average Ct and average ΔCt values from the discovery phase. In the discovery phase, the expression of miRNAs in whole saliva from patients with a malignant parotid gland tumor (n=10) were compared to the expression of miRNAs in whole saliva from patients with a benign parotid gland tumor (n=10).
Supplementary Figure 3 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 387KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplementary Figure 1 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 104KB, Supplementary Figure 1A-B: PC9GR cells acquired drug resistance to both reversible and irreversible EGFR-TKI. A: PC9 and PC9GR cells were treated for 72 h with increasing concentrations of erlotinib or CL387,785. Data generated by cell viability assay (CellTiter-Glo) are expressed as a percentage of the value for untreated cells. Determinations were done in triplicate. B: PC9 and PC9GR cells were incubated for 1 hour in the absence or presence of erlotinib (1 �M) as indicated. Cell lysates were subjected to protein expression analysis with antibodies to pEGFR, pSrc, pAkt, and pErk along with antibodies to β-actin as a loading control. C-D: Gene status in PC9 and PC9GR cells. C: PC9GR cells acquired T790M while retaining exon 19 deletion as determined by PCR-invader assay. Values of red bars above zero represent positive results with the detection probe for indicated mutation sequences of EGFR, while values of light blue bars are quality controls showing good PCR quality, as previously described (1). The value of red bars = (ﬂuorescence of the samples with detection probe for mutation sequences) - (ﬂuorescence of the normal control with the same probe � 2). The value of light blue bars = (ﬂuorescence of the samples with detection probe for wild type sequences) - (ﬂuorescence of the normal control with the same probe � 0.8). DEL1 represents E746-A750del type1 (2235-2249del GGAATTAAGAGAAGC). DEL2 represents E746-A750del type2 (2236-2250del GAATTAAGAGAAGCA). DEL3 represents L747-P753del insS. D: FISH analysis (CEP7 (green)/D7S522 (red)) was done in PC9 and PC9GR cells as previously described (2). No additional copy of D7S522 compared to CEP 7 was found in these cells, explaining that neither PC9 nor PC9GR cells has MET amplification.
Supplementary Table 2 from EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Authors: Bladt Friedhelm , Faden Bettina , Friese-Hamim Manja , Knuehl Christine , Wilm Claudia , Fittschen Claus , Grädler Ulrich , Meyring Michael , Dorsch Dieter , Jaehrling Frank , Pehl Ulrich , Stieber Frank , Schadt Oliver , Blaukat Andree
Published: April 2023

PDF file - 75K, High responsiveness of c-Met-addicted cell lines to treatment with EMD 1214063 and EMD 1204831. The impact of EMD 1214063 and EMD 1204831 on tumor cell viability (IC50) was tested in vitro, using a panel of tumor cell lines specifically characterized for their levels of c-Met expression, c-Met auto-phosphorylation, and HGF production. The human colorectal carcinoma cell line HT29 and the human lung carcinoma cell line A549 displayed low levels of c-Met/phospho-c-Met, while the lung carcinoma cell line EBC-1 and the gastric carcinoma Hs746T and MKN-45 exhibited high levels of both c-Met and phospho-c-Met, due to the described c-Met gene amplification (3). The c-Met-"addicted" cell lines (EBC-1 (4), Hs746T (3) and MKN-45 (3)), exhibited high sensitivity to both EMD 1214063 and EMD 1204831. In contrast, high concentrations of EMD 1214063 were required to induce 50% reduction in the viability of HT29 and A549. Similar to EMD 1214063, EMD 1204831 also showed strong impact on the viability of Hs746T cells (IC50 = 4.72E-09), EBC-1 (IC50 = 1.21E-08), and MKN-45 (IC50 = 4.93E-08). Data are cumulative of three separate experiments; the IC50 represent the mean of three separate experiments.
Supplementary Figure 5 from EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Authors: Bladt Friedhelm , Faden Bettina , Friese-Hamim Manja , Knuehl Christine , Wilm Claudia , Fittschen Claus , Grädler Ulrich , Meyring Michael , Dorsch Dieter , Jaehrling Frank , Pehl Ulrich , Stieber Frank , Schadt Oliver , Blaukat Andree
Published: April 2023

PDF file - 74K, Effective inhibition of c-Met phosphorylation in U87MG cells. To assess the pharmacodynamic activity of EMD 1214063 and EMD 1204831 in glioblastoma, U87MG glioblastoma cells were exposed for 2 h to either EMD compound. After lysis, the phosphorylation levels of c-Met Y1234/Y1235 auto-phosphorylation site (A) and of c-Met Y1349 adaptor binding site (B) were assessed and correlated with the levels of total c-Met by a Luminex-based assay. Y1234/Y1235 EC50 values for EMD 1214063 and EMD 1204831 were 0.003 �M and 0.009 �M, respectively. For Y1349, the EC50 values were 0.011 �M and 0.005 �M for EMD 1214063 and EMD 1204831, respectively. While a dose-dependent reduction in the levels of c-Met phosphorylation could be observed upon exposure to both compounds, the levels of total c-Met remained unchanged (C). Data are cumulative of three independent experiments.
Supplementary Figure 1 from EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Authors: Bladt Friedhelm , Faden Bettina , Friese-Hamim Manja , Knuehl Christine , Wilm Claudia , Fittschen Claus , Grädler Ulrich , Meyring Michael , Dorsch Dieter , Jaehrling Frank , Pehl Ulrich , Stieber Frank , Schadt Oliver , Blaukat Andree
Published: April 2023

PDF file - 45K, ATP competition studies with EMD 1214063. EMD 1214063 inhibited c-Met phosphorylation in an ATP-competitive fashion. In brief, binding competition of EMD 1214063 and ATP to c-Met was analyzed by a kinase reaction followed by Western blotting. ATP in the indicated concentrations was mixed with 1 nM EMD 1214063 and added to 100 ng recombinant human c-Met kinase (Carna Biosciences 08-151). The reaction mixtures were incubated at room temperature for 30 min. The reaction was stopped by addition of 4x LDS Sample Buffer (Invitrogen NP-0007) containing 25 mM DTT and heating at 80{degree sign}C for 20 min. The reaction mixtures were analyzed by Western blotting using 1 ng c-Met kinase per lane in gel electrophoresis. After blotting on nitrocellulose, detection was performed with an anti-phosphotyrosine antibody (clone PY99, Santa Cruz sc-7020) and an anti-GST-tag antibody (clone B-14, Santa Cruz sc-138) as a loading control. Chemiluminescence read out was measured with a VersDoc analyzer (BioRad) and band densities were quantified with the inherent software (ImageLab).
Supplementary Tables 1 - 4 from Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization
Authors: Wang Hong , Ru Yuanbin , Sanchez-Carbayo Marta , Wang Xuejiao , Kieft Jeffrey S. , Theodorescu Dan
Published: April 2023

PDF file - 136K, Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization Table S1. Clinicopathologic characteristics of bladder patient samples in microarray datasets Table S2. Clinicopathologic characteristics of prostate patient samples in microarray datasets Table S3. eIF3 subunits mRNA expression in normal bladder vs. bladder tumor Table S4. Half-life of selected proteins involved in current study.
Supplementary Figures 1 - 9 from Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization
Authors: Wang Hong , Ru Yuanbin , Sanchez-Carbayo Marta , Wang Xuejiao , Kieft Jeffrey S. , Theodorescu Dan
Published: April 2023

PDF file - 672K, Figure S1. High eIF3b mRNA expression is associated with human bladder cancer. Figure S2. eIF3b antibody specificity Figure S3. High eIF3b mRNA expression is associated with aggressive phenotypes in human prostate cancer Figure S4. Time course of eIF3b depletion. Figure S5. Depletion of eIF3b inhibits prostate cancer cell growth. Figure S6. Depletion of eIF3b affects the cell cycle in cancer cells. Figure S7. Depletion of eIF3b does not induce apoptosis in UMUC3 cells. Figure S8. Depletion of eIF3b decreases cell spreading and adhesion through integrin alpha5 in PC3 cells. Figure S9. Depletion of eIF3c inhibits cell growth, protein synthesis and disrupts actin cytoskeleton organization and focal adhesion.
Supplementary Figure Legend from Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer
Authors: Guo Xiaojing , Yang Chunying , Qian Xiaolong , Lei Ting , Li Yaqing , Shen Haifa , Fu Li , Xu Bo
Published: April 2023

Supplementary Figure Legend - PDF file 60K, Supplementary Figure S1: top panel: MCF-7 cells were transiently transfected with control of ER-alpha siRNA. RNA was extracted 48 hours after transfected and the level of ATM mRNA was measured by RT-PCR. Bottom panel: Expression of ATM mRNA in MCF-7 cells by Real-time PCR. Expression levels were normalized by GAPDH. Error bars represent mean SD calculated from 3 parallel experiments. Supplemental Figure S2: Predicted consequential pairing of target region of ATM (top) and miRNA (bottom) of MiRNAs 18a, 106a and 101. Supplemental Figure S3: MDA-MB-231 cells were co-transfected with a luciferase reporter plasmid along with miRNA-18a or miRNA 106a. Relative luciferase activities representing ATM 3'UTR and pMirTarget vector are presented. Shown are averages of triplicate samples and standard deviations. Student t tests were used to analyze the data. Supplemental Figure S4: MiRNAs 18a and 106a are under-expressed in ER negative breast cancer tissues. In situ hybridization was conducted in 296 cases of breast cancer tissues probing miRNAs 18a and 106a. Shown are representative images of miRNA 18a and 106 expressions
Supplementary Figures 1-11 from ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer
Authors: Kabbout Mohamed , Garcia Melinda M. , Fujimoto Junya , Liu Diane D. , Woods Denise , Chow Chi-Wan , Mendoza Gabriela , Momin Amin A. , James Brian P. , Solis Luisa , Behrens Carmen , Lee J. Jack , Wistuba Ignacio I. , Kadara Humam
Published: April 2023

Supplementary Figures 1-11 - PDF file 905K, Supplementary Figure 1. Decreased ETS2 expression in smoker lung adenocarcinomas compared to adenocarcinomas from never-smoker patients. Supplementary Figure 2. ETS2 expression in never-smoker and smoker lung cancer cell lines. Supplementary Figure 3. IHC analysis of ETS2 protein in NSCLC FFPE histological tissue specimens. Supplementary Figure 4. Over-expression of ETS2 decreases lung cancer cell anchorage-dependent and -independent growth. Supplementary Figure 5. Modulation of HGF-mediated gene-interaction network following knockdown of ETS2 in H441 lung cancer cells. Supplementary Figure 6. Increased phospho-MET levels following ETS2 knockdown. Supplementary Figure 7. Over-expression of ETS2 decreases MET phosphorylation in lung cancer cells. Supplementary Figure 8. HGF treatment increases ETS2 levels in lung cancer cells. Supplementary Figure 9. ETS2 inhibits HGF-induced lung cancer cell proliferation and migration. Supplementary Figure 10. IHC analysis of phosphorylated MET protein in NSCLC FFPE histological tissue specimens. Supplementary Figure 11. NSCLC patients with both low ETS2 and high membrane phospho-MET IHC expression exhibit significantly reduced time to recurrence